Literature DB >> 17896806

Bone mineral density in older adult patients with rheumatoid arthritis: an analysis of NHANES III.

Mitsuyo Kinjo1, Soko Setoguchi, Daniel H Solomon.   

Abstract

OBJECTIVE: Several studies suggest that bone mineral density (BMD) is reduced in rheumatoid arthritis (RA). However, it is unclear whether this relationship holds in a representative community-based typical RA population. We examined the relationship between BMD and RA in a representative US population-based sample from the Third National Health and Nutrition Examination Survey (NHANES III: 1988-1994).
METHODS: We selected subjects over age 60 with RA from NHANES III using previously described methods. Femoral neck BMD (FN-BMD) measured by dual-energy x-ray absorptiometry was compared for the RA (n = 106) and non-RA cohorts (n = 4,277). Multivariable linear regression models included known risk factors for osteoporosis. Further adjusted analyses compared the BMD among subgroups of patients with RA, such as those taking methotrexate (MTX), those with positive rheumatoid factor (RF), and those with elevated C-reactive protein (CRP).
RESULTS: Patients with RA more frequently reported poor health, a history of falling, cognitive impairment, early menopause, a history of chronic obstructive lung disease, higher total calcium intake, and thiazide use than the non-RA subjects (all p < 0.05). Adjusted FN-BMD was similar between the patients with RA (0.71 g/cm2) and non-RA subjects (0.72 g/cm2; p = 0.5). Among patients with RA, reduced BMD tended to be seen with MTX use (0.60 g/cm2, p = 0.07), CRP above 1 mg/dl (0.66 g/cm2, p = 0.09), and positive RF in female patients (0.68 g/cm2, p = 0.056). However, none of these findings reached statistical significance.
CONCLUSIONS: Among a US population-based representative sample, FN-BMD was similar in RA and non-RA patients. Several characteristics of patients with RA may be associated with reduced BMD.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17896806

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  6 in total

Review 1.  Osteoporosis drug therapy strategies in the setting of disease-modifying agents for autoimmune disease.

Authors:  B F Ricciardi; J Paul; A Kim; L A Russell; J M Lane
Journal:  Osteoporos Int       Date:  2012-09-07       Impact factor: 4.507

2.  Risk of osteoporotic fracture in a large population-based cohort of patients with rheumatoid arthritis.

Authors:  Seo Young Kim; Sebastian Schneeweiss; Jun Liu; Gregory W Daniel; Chun-Lan Chang; Katie Garneau; Daniel H Solomon
Journal:  Arthritis Res Ther       Date:  2010-08-03       Impact factor: 5.156

3.  Bone mineral density changes in patients with recent-onset rheumatoid arthritis.

Authors:  Eman A Hafez; Howaida E Mansour; Sherin H Hamza; Sherine George Moftah; Takwa Badr Younes; Mona Ahmed Ismail
Journal:  Clin Med Insights Arthritis Musculoskelet Disord       Date:  2011-10-09

4.  Characteristics and risk factors of rheumatoid arthritis in the United States: an NHANES analysis.

Authors:  Bei Xu; Jin Lin
Journal:  PeerJ       Date:  2017-11-24       Impact factor: 2.984

5.  Impact of Rheumatoid Arthritis and Its Management on Falls, Fracture and Bone Mineral Density in UK Biobank.

Authors:  Michael A Clynes; Karen Jameson; Daniel Prieto-Alhambra; Nicholas C Harvey; Cyrus Cooper; Elaine M Dennison
Journal:  Front Endocrinol (Lausanne)       Date:  2019-11-26       Impact factor: 5.555

6.  Clinical and Radiological Characterization of Patients with Immobilizing and Progressive Stress Fractures in Methotrexate Osteopathy.

Authors:  Tim Rolvien; Nico Maximilian Jandl; Julian Stürznickel; Frank Timo Beil; Ina Kötter; Ralf Oheim; Ansgar W Lohse; Florian Barvencik; Michael Amling
Journal:  Calcif Tissue Int       Date:  2020-10-16       Impact factor: 4.333

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.